Skyrizi (Risankizumab) for Moderate-to-Severe Plaque Psoriasis
For adults with moderate-to-severe plaque psoriasis who have failed conventional systemic therapy, administer Skyrizi 150 mg subcutaneously at week 0, week 4, and then every 12 weeks thereafter. 1
Dosing Regimen
The FDA-approved dosing for plaque psoriasis is straightforward and highly effective:
- Loading doses: 150 mg subcutaneous injection at week 0 and week 4
- Maintenance: 150 mg every 12 weeks thereafter 1
This is a self-administered subcutaneous injection that patients can perform after proper training. The dosing interval is notably convenient compared to other biologics—every 3 months rather than weekly, biweekly, or monthly schedules required by many alternatives 1.
Pre-Treatment Screening
Before initiating Skyrizi, complete the following screening:
- Tuberculosis testing: Perform tuberculin skin test (PPD) or interferon-gamma release assay (IGRA). Treat latent TB before starting Skyrizi 1
- Hepatitis B screening: Test for HBsAg and anti-HBc. If positive, consult hepatology before initiation 1
- Vaccination status: Complete all age-appropriate vaccinations per current immunization guidelines before starting therapy. Inactivated vaccines can be given during treatment, but avoid live vaccines while on Skyrizi 1, 2
- Baseline laboratory work: While not explicitly required by the FDA label, obtain baseline CBC and comprehensive metabolic panel as standard practice for biologic initiation
Do not perform routine interval laboratory monitoring—there is no requirement for ongoing blood work during Skyrizi treatment, unlike methotrexate or cyclosporine 1.
Safety Monitoring During Treatment
Infection Surveillance
Monitor clinically for signs and symptoms of infection. Stop Skyrizi if a serious infection develops until the infection resolves 1. The infection risk is slightly elevated compared to placebo (OR 1.38,95% CI 0.87-2.18) but remains acceptable 3. Serious infection rates are low at 1.2 per 100 patient-years with long-term use 4.
Malignancy Monitoring
Perform routine age-appropriate cancer screening. Long-term data through 6 years shows:
- Non-melanoma skin cancer: 0.7 per 100 patient-years
- Malignant tumors excluding NMSC: 0.5 per 100 patient-years 4
These rates are reassuring, though the effect on solid tumor or lymphoreticular malignancy remains incompletely defined and requires ongoing surveillance 2.
Cardiovascular Events
No specific monitoring required beyond standard cardiovascular risk management. Major adverse cardiovascular event rates are low at 0.3 per 100 patient-years 4.
Efficacy Expectations
Set appropriate patient expectations based on robust clinical trial data:
By week 16 (primary endpoint timeframe):
- PASI 90: 72-75% of patients achieve ≥90% improvement 5, 6
- PASI 100: Complete clearance in 30-45% of patients 2
- sPGA 0/1 (clear or almost clear): 84-88% of patients 5, 6
Long-term outcomes at 6 years:
- PASI 90: 86% maintained response
- PASI 100: 54% complete clearance
- Quality of life (DLQI 0/1): 76% 7
Assess treatment response definitively at 12 weeks 2. If response is inadequate, consider adding topical corticosteroids, vitamin D analogues, methotrexate, or narrowband UVB phototherapy, though combination data are limited 2.
High-Impact Site Effectiveness
Skyrizi demonstrates excellent efficacy in difficult-to-treat areas:
- Scalp psoriasis: 60.8% achieve IGA 0/1 at week 16; 72.5% complete clearance at 2 years 8, 9
- Genital psoriasis: 69.1% achieve sPGA-G 0/1 at week 16 9
- Nail psoriasis: 64.7% complete clearance at 2 years 8
- Palmoplantar psoriasis: 52.2% complete clearance at 2 years 8
Special Circumstances
Surgery
Continue Skyrizi through low-risk surgical procedures (no break in sterile technique, no entry into respiratory/GI/GU tracts). For moderate- to high-risk surgery, consider discontinuing approximately 3-4 half-lives before surgery (roughly 4-5 months given risankizumab's long half-life) and resume 1-2 weeks postoperatively if no complications 2.
Missed Doses
If a dose is missed, administer as soon as possible, then resume the regular 12-week schedule 1. If more than 3-4 half-lives have passed or the patient is flaring, consider repeating the loading doses (week 0 and week 4 dosing) 2.
Pregnancy and Lactation
The FDA label does not provide specific guidance. Use clinical judgment and discuss risks/benefits, as data are limited. Based on the 2019 AAD-NPF guidelines for other biologics, there may be theoretical risks with third-trimester use due to transplacental transfer 2.
Comparative Effectiveness
Skyrizi demonstrates superior efficacy compared to other biologics:
- vs. Ustekinumab: PASI 90 at week 16: 75% vs. 42-48% (p<0.0001) 5
- vs. Adalimumab: PASI 90 at week 16: 72% vs. 47% (p<0.0001) 6
- Network meta-analysis ranking: Bimekizumab > Risankizumab > Guselkumab > Secukinumab > Adalimumab > Ustekinumab 10
Risankizumab ranks as the second most effective biologic after bimekizumab for achieving PASI 90 at week 16 10.
Administration Technique
- Allow the prefilled pen or syringe to reach room temperature (30-90 minutes for pen, 15-30 minutes for syringe) before injection 1
- Inject into abdomen, thigh, or upper outer arm (arm administration requires healthcare professional or caregiver) 1
- Avoid areas where skin is tender, bruised, red, indurated, or affected by psoriasis 1
- Rotate injection sites 1
Common Pitfalls to Avoid
- Do not delay treatment for extensive laboratory monitoring—only TB and hepatitis B screening are required pre-treatment
- Do not order routine interval labs—unlike traditional systemics, no ongoing monitoring is needed
- Do not give live vaccines during treatment—complete vaccinations before starting or use inactivated vaccines only
- Do not discontinue prematurely—allow full 12-16 weeks to assess response before declaring treatment failure
- Do not assume failure with other biologics predicts Skyrizi failure—patients who fail other biologics, including ustekinumab, can still respond well to risankizumab 2